Status:
COMPLETED
Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia
Lead Sponsor:
Shire
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This is a multiple ascending dose study; the purpose of this study is to examine the safety, tolerability and pharmacokinetics (levels of drug in the blood) of SPD489 in Schizophrenic Patients who are...
Eligibility Criteria
Inclusion
- Subjects must be diagnosed with schizophrenia, on a stable dose of an antipsychotic and not have any cardiac risk factors
Exclusion
Key Trial Info
Start Date :
October 21 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 20 2012
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01457339
Start Date
October 21 2011
End Date
January 20 2012
Last Update
June 3 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
California Clinical Trials
Glendale, California, United States, 91206
2
Collaborative Neuroscience Network, Inc
Long Beach, California, United States, 90806